Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance.
- NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_assertion description "[DNA methyltransferase (DNMT) inhibitors, azacitidine (Vidaza, Pharmion, Boulder, CO, USA) and decitabine (Dacogen; SuperGen Inc, Dublin, CA, USA, and MGI Pharma Inc, Bloomington, MN, USA), have had a significant impact on the treatment paradigm of myelodysplastic syndromes (MDSs), previously managed mainly by supportive care and hematopoietic-stem-cell transplantation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance.
- NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_assertion evidence source_evidence_literature NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance.
- NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_assertion SIO_000772 16341239 NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance.
- NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_assertion wasDerivedFrom befree-20140225 NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance.
- NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_assertion wasGeneratedBy ECO_0000203 NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance.
- befree-20140225 importedOn "2014-02-25" NP312518.RAZOOTNb4ZxcaDFkx_b54yVcteBrdzPFLzbBreCCS07_g130_provenance.